CreditReports.dk
HomeScreen companies

Breye Therapeutics ApS Financials, key figures and credit report

CVR number: 40279865 Established 2019 Industry: 21 Manufacture of basic pharmaceutical products and pharmaceutical preparations
Company contact details
Agern Alle 24, 2970 Hørsholm
Gross profit -7 655.4 kDKK FY 2025 -1.5% vs 2024
EBIT -72 318.6 kDKK FY 2025 +12.5% vs 2024
Net debt 87 569.5 kDKK FY 2025 +254.3% vs 2024
Quick ratio 2.7 FY 2025 +2.2 vs 2024

Income statement (kDKK)

2021
2022
2023
2024
2025
Fiscal period length1212121212
Net sales
Other operating income138.4613.75
External services- 673.85-2 896.50-7 812.13-7 545.56-7 655.44
Gross profit- 535.39-2 882.75-7 812.13-7 545.56-7 655.44
Employee benefit expenses-1 013.69-1 716.58-6 406.88-7 079.53-8 924.99
Other operating expenses-6 640.32-15 236.75-60 742.15-67 617.12-55 341.14
Total depreciation- 411.17- 397.05- 397.05
EBIT-8 189.40-19 836.07-75 372.33-82 639.25-72 318.62
Other financial income167.1433.94817.19367.71558.48
Other financial expenses-1 231.95- 900.03-1 090.61-12 368.31-19 315.16
Net income from associates (fin.)-1 540.45-74.77
Pre-tax profit-10 794.66-20 776.94-75 645.75-94 639.85-91 075.30
Income taxes6 202.065 495.705 500.005 500.00
Net earnings-10 794.66-14 574.88-70 150.06-89 139.85-85 575.30

Assets (kDKK)

2021
2022
2023
2024
2025
Development expenditure5 161.654 764.60
Intangible rights5 955.755 558.70
Intangible assets total5 955.755 558.705 161.654 764.60
Machinery and equipment31.7717.6517.6517.65
Tangible assets total31.7717.6517.6517.65
Holdings in group member companies0.010.010.010.010.01
Investments total0.0152.7554.0793.6395.99
Long term receivables total
Inventories total
Current amounts owed by group member comp.251.42153.68153.6812.5612.56
Prepayments and accrued income1.25155.87314.331 770.02
Current other receivables361.17878.182 583.951 431.18988.16
Current deferred tax assets6 202.065 500.005 500.005 500.00
Short term receivables total613.847 389.798 551.958 713.776 500.72
Cash and bank deposits2 514.3911 385.3446 499.4943 060.9229 206.42
Cash and cash equivalents2 514.3911 385.3446 499.4943 060.9229 206.42
Balance sheet total (assets)3 128.2424 815.4060 681.8657 047.6340 585.38

Equity and liabilities (kDKK)

2021
2022
2023
2024
2025
Share capital53.50133.03325.09341.67341.67
Retained earnings-5 628.2428 968.23118 310.4448 160.38-40 979.46
Profit of the financial year-10 794.66-14 574.88-70 150.06-89 139.85-85 575.30
Shareholders equity total-16 369.4014 526.3848 485.47-40 637.79- 126 213.09
Non-current loans from credit institutions18 477.987 100.903 766.811 944.06114 641.63
Non-current other liabilities39 145.95
Non-current liabilities total18 477.987 100.903 766.811 944.06153 787.57
Current loans from credit institutions527.003 090.0065 834.392 134.28
Current trade creditors909.682 526.494 766.559 524.1010 308.26
Current owed to participating8.778.77
Other non-interest bearing current liabilities101.20125.87573.0320 382.86568.36
Current liabilities total1 019.653 188.128 429.5895 741.3613 010.90
Balance sheet total (liabilities)3 128.2424 815.4060 681.8657 047.6340 585.38
Page generated